Axsome Therapeutics, Inc. — Form 8-K
Filed July 15, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Axsome announced FDA acceptance of its New Drug Application (NDA) for AXS-12 (reboxetine) to treat cataplexy in narcolepsy, with a PDUFA target action date of May 1, 2027. The FDA indicated it does not plan to hold an advisory committee meeting. AXS-12 has orphan drug designation; cataplexy affects ~70% of narcolepsy patients. No specific commercial or financial terms were disclosed in the filing.
Why this rating
NDA acceptance is meaningful milestone for $4.4B biotech; orphan disease with 70% prevalence in patient population. However, 10-month regulatory timeline and no advisory committee flag low immediate risk, tempering upside versus full approval.
See more from July 15, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.